Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

CellCentric selects Sygnature Discovery for Epigenetic Prostate Cancer Programme

publication date: Oct 21, 2013
 | 
author/source: Sygnature Discovery Limited

Sygnature Discovery, a leading provider of integrated drug discovery services, today announced that it has been selected by CellCentric, a biotechnology company with a scientific foundation in epigenetics, to progress small molecule inhibitor drug discovery against a specific deubiquitinase (DUB) enzyme which has been demonstrated to play a key role in the progression of prostate cancer.

sygnature discovery logoCellCentric recently received £4.3 million through further venture investment and an award from the UK government-backed Technology Strategy Board’s BioMedical Catalyst Fund, to further fuel the DUB programme through to small molecule clinical candidates.  The new agents act upon the androgen receptor (AR) pathway, which is gaining significant interest from the pharmaceutical industry. CellCentric’s approach has the potential to modulate AR and AR splice variants, which could be key to overcoming many of the drug resistance mechanisms which limit the clinical benefit of existing approved and developmental therapeutic agents.
 
Dr Will West, Chief Executive Officer, CellCentric said: “We are delighted with the continued support from our shareholders and from the BioMedical Catalyst award. The further funding should see us progress our main programme through to significant clinical and commercial value.  The application of epigenetics to novel drug discovery is now maturing beyond just the promise of a new scientific area.  We look forward to expanding our excellent relationship with Sygnature Discovery who have a growing reputation for high quality integrated drug discovery services, and who will help us to achieve our corporate goals.”
 
Dr Simon Hirst, Chief Executive Officer, Sygnature Discovery said: “We are pleased that CellCentric has selected Sygnature Discovery to be its drug discovery partner.  Epigenetics is a rapidly evolving field and this is an exciting opportunity for us to work on an unexplored and challenging drug target which has been shown to be critical in prostate cancer.  Sygnature has considerable in-house oncology drug discovery knowledge and having medicinal chemistry, computational chemistry and in vitro screening under one roof will enable us to accelerate CellCentric’s prostate cancer programme towards the clinic.”


more about Sygnature Discovery


more about Integrated Drug Discovery


more about Cellcentric




 

News Channels

 

 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 

 

 

 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events